[1]吴　婕,张英杰,周华君,等.慢性HBV感染者血清持续低水平HBsAg表达免疫耐受机制的研究进展[J].现代检验医学杂志,2022,37(02):199-204.[doi:10.3969/j.issn.1671-7414.2022.02.040]
　WU Jie,ZHANG Ying-jie,ZHOU Hua-jun,et al.doi:10.3969/j.issn.1671-7414.2022.02.040 Research Progress on Immune Tolerance Mechanism of Persistent Low-level Serum HBsAg Expression in Patients with Chronic HBV Infection[J].Journal of Modern Laboratory Medicine,2022,37(02):199-204.[doi:10.3969/j.issn.1671-7414.2022.02.040]
点击复制

慢性HBV感染者血清持续低水平HBsAg表达免疫耐受机制的研究进展()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年02期
页码:
199-204
栏目:
综　述
出版日期:
2022-03-15

文章信息/Info

Title:
doi:10.3969/j.issn.1671-7414.2022.02.040 Research Progress on Immune Tolerance Mechanism of Persistent Low-level Serum HBsAg Expression in Patients with Chronic HBV Infection
文章编号:
1671-7414（2022）02-199-06
作者:
吴　婕1; 张英杰1; 周华君2; 成　军2
（1. 蚌埠医学院检验医学院，安徽蚌埠 233000；2. 中国人民解放军联勤保障部队第九〇三医院，杭州 310013）
Author(s):
WU Jie1;  ZHANG Ying-jie1;  ZHOU Hua-jun2;  CHENG Jun2
(1. School of Laboratory Medicine, Bengbu Medical College, Anhui Bengbu 233000, China; 2. Department of Clinical Research, the 903rd Hospital of PLA, Hangzhou 310013, China)
关键词:
乙型肝炎表面抗原; 持续低水平表达; 免疫耐受
分类号:
R512.62；R392.11
DOI:
10.3969/j.issn.1671-7414.2022.02.040
文献标志码:
A
摘要:
乙型肝炎是一种常见的感染性疾病，乙型肝炎表面抗原（hepatitis B surface antigen, HBsAg）是乙型肝炎病毒（hepatitis B virus, HBV）感染的重要血清标志物之一。慢性HBV 感染者血清持续低水平HBsAg 表达是在多种因素的综合作用下，HBV 自身复制与宿主免疫清除达到一种相对稳定而复杂的动态平衡状态，其HBV DNA 呈现低复制，因此，HBV感染者血清持续低水平HBsAg状态下仍具有潜在传染风险性，已受到了传染病学、流行病学等领域专家的广泛关注。目前，有关血清持续低水平HBsAg 表达的形成机制尚不完全明确，但持续低水平HBsAg 表达形成机制中存在着宿主免疫耐受现象被广大学者所认可，然而如何打破宿主对持续低水平HBsAg 表达的免疫耐受，实现宿主对病毒的清除是现阶段面临的严峻挑战，为此该文对慢性HBV感染者血清持续低水平HBsAg 表达免疫耐受机制的相关研究进展进行综述，为打破免疫耐受、有效清除低水平HBV 提供新思路。
Abstract:
Hepatitis B is a common infectious disease, and hepatitis B surface antigen (HBsAg) is one of the important serum markers of hepatitis B virus (HBV) infection. The persistent low level of HBsAg expression in the serum of chronic HBV infected persons is a relatively stable and complex dynamic equilibrium state between HBV self-replication and host immune clearance under the comprehensive action of various factors, and its HBV DNA presents low replication. Therefore, the persistent low level of HBsAg in the serum of HBV infect persons still has potential infectious risk, which has been subject to infectious diseases extensive attention of experts in epidemiology and other fields. At present, the formation mechanism of sustained low-level HBsAg expression in serum is not completely clear, but the phenomenon of host immune tolerance in the formation mechanism of sustained low-level HBsAg expression is recognized by the majority of scholars. However, how to break the host’s immune tolerance to sustained low-level HBsAg expression and realize the host’s clearance of virus is a major challenge at this stage, therefore, this paper reviews the relevant research progress on the immune tolerance mechanism of persistent lowlevel HBsAg expression in patients with chronic HBV infection, so as to provide a new idea for breaking immune tolerance and effectively clearing low-level HBV.

参考文献/References:

[1] SMALLS D J, KIGER R E, NORRIS L B, et al. Hepatitis B virus reactivation: risk factors and current management strategies[J]. Pharmacotherapy, 2019, 39(12): 1190-1203.
[2] TOUT I, LOUREIRO D, MANSOURI A, et al. Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development[J]. Journal of Hepatology, 2020, 73(2): 409-422.
[3] LIU Yayun, LIANG Xuesong. Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA[J]. World Journal of Hepatology, 2018, 10(9): 603-611.
[4] 韩振格, 杨美娟, 吴萍, 等. 体检人群血清低水平 HBsAg 携带状况调查[J]. 中华检验医学杂志, 2009, 32 (10): 1167-1168. HAN Zhenge, YANG Meijuan, WU Ping, et al. Investigation on low level of HBsAg in physical examination population[J].Chinese Journal of Laboratory Medicine, 2009, 32(10): 1167-1168.
[5] 邓安彦, 蔡艳娟, 周守容, 等.ELISA 法检测 HBsAg （CMIA）低值血清样本的结果分析[J]. 现代检验 医学杂志, 2015, 30(2): 123-125. DENG Anyan, CAI Yanjuan, ZHOU Shourong, et al. Analysis of the results of ELISA by detecting low quantitative HBsAg(CMIA) in serums [J]. Journal of Modern Laboratory Medicine, 2015, 30(2): 123-125.
[6] 刘立, 刘春云, 李俊义, 等．低水平HBsAg 患者 肝脏组织病理变化分析[J]. 重庆医学, 2018, 47(8): 1109-1111. LIU Li, LIU Chunyun, LI Junyi, et al. Pathological changes of liver tissue in patients with low level HBsAg[J].Chongqing Medical, 2018, 47(8): 1109-1111.
[7] 熊洪海. 干扰素联合恩替卡韦治疗低水平乙型肝炎 表面抗原和低水平乙型肝炎病毒载量患者的临床效 果[J]. 医疗装备, 2020, 33(24): 8-10. XIONG Honghai. Clinical effect of interferon combined with entecavir in the treatment of patients with low level of hepatitis B surface antigen and low level of hepatitis B virus load [J]. Medical Equipment, 2020, 33(24): 8-10.
[8] JIN Zizheng, JIN Fangfang, LIU Xin, et al. Coexistence of low levels of HBsAg and high levels of anti-HBs may increase risk of hepatocellular carcinoma in chronic hepatitis B patients with high HBV load[J]. The Brazilian Journal of Infectious Disease, 2019, 23(5): 343-351.
[9] DAI Yuzhu, CHE Feihu, JIANG Xiao, et al. Clinical characteristics and association analysis of persistent low-level HBsAg expression in a physical examination population with HBV infection[J].Exp Ther Med, 2019, 19(1): 19-32.
[10] SADEGHI A, SHIRVANI-DASTGERDI E, TACKE F, et al. HBsAg mutations related to occult hepatitis B virus infection in HIV-positive patients result in a reduced secretion and conformational changes of HBsAg[J]. Journal of Medical Virology, 2017, 89(2): 246-256.
[11] WANG Tong, DAI Yuzhu, ZHANG Meng, et al. Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg[J]. Int J Mol Med, 2018, 42(5): 2689-2699.
[12] LIU Yang, ZHAO Zhonghua, L? Xiaoqin, et al. Precise analysis of the effect of basal core promoter/precore mutations on the main phenotype of chronic hepatitis B in mouse models[J]. Journal of Medical Virology,2020, 92(12):26025.
[13] GRAUMANN F, CHURIN Y, TSCHUSCHNER A, et al. Genomic methylation inhibits expression of hepatitis B virus envelope protein in transgenic mice: a non-infectious mouse model to study silencing of HBV surface antigen genes[J].PLoS One, 2015, 10(12): e0146099.
[14] NINOMIYA M, KONDO Y, KIMURA O, et al. The expression of miR-125b-5p is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen[J]. Journal of Viral Hepatitis, 2016, 23(5): 330-339.
[15] WEI Zhiqiang, ZHANG Yonghong, KE Changzheng, et al. Curcumin inhibits hepatitis B virus infection by down-regulating ccc DNA-bound histone acetylation[J]. World Journal of Gastroenterology, 2017, 23(34): 6252- 6260.
[16] YAN Ying, ALLWEISS L, YANG Danli, et al. Downregulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection[J]. Emerging Microbes & Infections, 2019, 8(1): 879-894.
[17] WU Jiafeng, HSU Hongyuan, CHIU Yuchun, et al. The effects of cytokines on spontaneous hepatitis B surface antigen seroconversion in chronic hepatitis B virus infection[J].The American Association of Immunologists, 2015, 194(2): 690-696.
[18] WANG Tong, ZHANG Meng, ZHOU Huajun, et al. Establishment and evaluation of a general dissociation technique for antibodies in circulating immune complexes[J].Clinical and Experimental Medicine, 2019, 19(1): 65-75.
[19] 王童, 成军．慢性HBV 感染者HBsAg 低水平表 达形成机制的研究进展[J]. 临床检验杂志, 2019, 37(10):768-772. WANG Tong, CHENG Jun. Research progress on the mechanism of low level expression of HBsAg in patients with chronic HBV infection[J]. Chinese Journal of Clinical Laboratory Science, 2019, 37(10): 768-772.
[20] 翁美玲, 张国梁, 吴文泽, 等．慢性乙型肝炎与 IFNγ, IL-4 的关系[J]. 临床肝胆病杂志, 2016, 32 (10):1989-1993． WENG Meiling, ZHANG Guoliang, WU Wenze, et al. Association of chronic hepatitis B with interferon-γ and interleukin-4[J].Journal of Clinical Hepatology, 2016, 32 (10): 1989-1993.
[21] 冯天同, 朱传龙. 慢性乙型肝炎治疗性疫苗的研究 现状及展望[J]. 医学研究生学报, 2021, 34 (2): 113- 118. FENG Tiantong, ZHU Chuanlong. Progress and prospect of therapeutic vaccination against chronic hepatitis B [J]. Journal of Medical Postgraduates, 2021, 34 (2): 113-118.
[22] HERRSCHER C, ROINGEARD P, BLANCHARD E.Hepatitis B virus entry into cells[J].Cells (Basel, Switzerland), 2020, 9(6): 1486.
[23] BETZ-STABLEIN B D, T?PFER A, LITTLEJOHN M, et al. Single-Molecule sequencing reveals complex genome variation of hepatitis B virus during 15 years of chronic infection following liver transplantation[J]. Journal of Virology, 2016, 90(16): 7171-7183.
[24] JIANG Bingfu, HILDT E. Intracellular trafficking of HBV particles[J]. Cells (Basel, Switzerland), 2020, 9(9): 2023.
[25] 张凯, 刘妍, 陈容娟, 等. 隐匿性HBV 感染相关S 基因突变对HBsAg 检测的影响及其机制[J]. 解放军 医学杂志, 2017, 42(10): 865-869. ZHANG Kai, LIU Yan, CHEN Rongjuan, et al. Analysis of the influence of nine occult HBV infectionrelated S-gene mutations on HBsAg detection [J]. Medical Journal of Chinese People’s Liberation Army, 2017, 42(10): 865-869.
[26] KIRDAR S, YA?A M H, SAYAN M, et al. HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment[J]. Mikrobiyoloji Bulteni, 2019, 53(2): 144-155.
[27] HORST A K,NEUMANN K, DIEHL L, et al. Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells[J]. Cellular & Molecular Immunology, 2016, 13(3, SI): 277-292.
[28] YU Jialli, GREEN M D, LI Shasha, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination[J]. Nature Medicine, 2021, 27(1): 152-164.
[29] LI Fenglei, TIAN Zhigang. The liver works as a school to educate regulatory immune cells[J]. Cellular & Molecular Immunology, 2013, 10(4): 292-302.
[30] ZHENG Meijuan, TIAN Zhigang. Liver-mediated adaptive immune tolerance[J]. Frontiers in Immunology, 2019, 10: 2525.
[31] DOHERTY D G. Immunity, t o l e r a n c e a n d autoimmunity in the liver: A comprehensive review[J]. Journal of Autoimmunity, 2016, 66: 60-75.
[32] GAO Bin. Basic liver immunology[J]. Cellular & Molecular Immunology, 2016, 13(3): 265-266.
[33] KUBES P, JENNE C. Immune responses in the liver[J]. Annual Review of Immunology, 2018, 36: 247-277.
[34] SUN Xiaoyue, YANG Xiaoqiang, ZENG Chui, et al. Modeling hepatitis B virus infection in Non-Hepatic 293T-NE-3NRs cells[J]. Journal of Visualized Experiments, 2020(160). DOI:10.3791/61414.
[35] MA Siyuan, CHEN Xiaohua, TAN Quanhui, et al. An engineered DC-Targeting lentivector induces robust T cell responses and inhibits HBV replication in HBV transgenic mice via upregulating T cell autophagy[J]. Cellular Physiology and Biochemistry, 2018, 48(3): 1041-1059.
[36] FISICARO P, BARILI V, ROSSI M, et al. Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches[J]. Frontiers in Immunology, 2020, 11: 849.
[37] SUKRITI S, TREHANPATI N, KUMAR M, et al. Functionally aberrant dendritic cell subsets and expression of DC-SIGN differentiate acute from chronic HBV infection[J]. Hepatology International, 2016, 10(6): 916-923.
[38] WIJAYA R S, READ S A, SCHIBECI S, et al. Expansion of dysfunctional CD56-CD16+ NK cells in chronic hepatitis B patients[J]. Liver International, 2021, 41(5): 969-981.
[39] SHAO Xue, MA Jingting, JIA Shengnan, et al. Interleukin-35 suppresses antiviral immune response in chronic hepatitis B virus infection[J]. Frontiers in Cellular and Infection Microbiology, 2017, 7: 472.
[40] 林春景, 吴金明. 乙型肝炎病毒感染免疫耐受机制 的研究进展[J]. 国际流行病学传染病学杂志, 2007, 34 (4):274-277, 280. LIN Chunjing, WU Jinming. Mechanisms of immune tolerance of hepatitis B virus infection [J]. International Journal of Epidemiology and Infectious Disease, 2007, 34 (4): 274-277,280.
[41] CAO Hui, ZHANG Ruiwen, ZHANG Wei. CTLA- 4 interferes with the HBV-specific T cell immune response (Review)[J].International Journal of Molecular Medicine, 2018, 42(2): 703-712.
[42] DOLINA J S, BRACIALE T J, HAHN Y S. Liverprimed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-cell immunoglobulin and mucin 3 engagement of highmobility group box 1 in mice[J]. Hepatology (Baltimore, Md.), 2014, 59(4): 1351-1365.
[43] LI Tianyang, YANG Yang, ZHOU Guo, et al. Immune suppression in chronic hepatitis B infection associated liver disease: A review[J]. World Journal of Gastroenterology, 2019, 25(27): 3527-3537.
[44] KIM J H, GHOSH A, AYITHAN N, et al. Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients[J]. Scientific Reports, 2020, 10(1): 1835.
[45] 成军, 孙长贵, 陈瑜, 等．低浓度HBsAg 人群临床 特征及免疫功能测定分析[J]. 细胞与分子免疫学杂 志, 2008, 24(12):1187-1189. CHENG Jun, SUN Changgui, CHEN Yu, et al. Clinical characteristics and immune function analysis of low concentration HBsAg population [J]. Chinese Journal of Cellular and Molecular Immunology, 2008, 24 (12): 1187-1189.
[46] LIU Pingyi, CHEN Lingling, ZHANG Haiyan. Natural killer cells in liver disease and hepatocellular carcinoma and the NK cell-based immunotherapy[J]. Journal of Immunology Research, 2018, 2018:1206737.
[47] LI Haijun, ZHAI Naicui, WANG Zhongfeng, et al. Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection[J]. Gut, 2018, 67(11): 2035-2044.
[48] FISICARO P, ROSSI M, VECCHI A, et al. The good and the bad of natural killer cells in virus control: perspective for Anti-HBV therapy[J]. International Journal of Molecular Sciences, 2019, 20(20): 5080.
[49] ZHENG Bingqing, YU Yating, PAN Zhaoyi, et al. HBsAg dampened STING associated activation of NK cells in HBeAg-negative CHB patients[J]. International Journal of Molecular Sciences, 2021, 22(14): 7643.
[50] AYITHAN N, TANG L, TAN S K, et al. Follicular Helper T (TFH) cell targeting by TLR8 signaling for improving hbsag-specific B cell response in chronic hepatitis B patients[J].Front Immunol,2021 ,12:735913.
[51] TANIGUCHI H, IWASAKI Y, AIMI M, et al. Clinical features of chronic hepatitis B patients with low hepatitis B surface antigen levels and determinants of hepatitis B surface antigen seroclearance[J]. JGH Open, 2020, 4(4): 698-706.
[52] YUEN L, REVILL P A, ROSENBERG G, et al. HBV variants are common in the ’immune-tolerant’ phase of chronic hepatitis B[J]. Journal of Viral Hepatitis, 2020, 27(10): 1061-1070.
[53] ALLAIN J P, OPARE-SEM O. Screening and diagnosis of HBV in low-income and middle-income countries[J]. Nature Reviews Gastroenterology & Hepatology, 2016, 13(11): 643-653.

相似文献/References:

[1]陈 慎,郑水华,易素芳,等.乙肝肝硬化患者血清HBsAg与HBVDNA比值在不同病程差异及疗效价值研究[J].现代检验医学杂志,2018,33(04):39.[doi:10.3969/j.issn.1671-7414.2018.04.010]
　CHEN Shen,ZHENG Shui-hua,YI Su-fang,et al.Difference of the Ratio of HBsAg to HBV DNA in Patients with Different Severity of Chronic Hepatitis B Virus Infection and Predictive Value for Clinical Effects[J].Journal of Modern Laboratory Medicine,2018,33(02):39.[doi:10.3969/j.issn.1671-7414.2018.04.010]

备注/Memo

备注/Memo:
基金项目：浙江省自然科学基金（LY15H 200001）。
作者简介：吴婕（1997-），女，检验技师，在读硕士，研究方向：分子免疫诊断，E-mail:2283243038@qq.com。
通讯作者：成军（1967-），男，主任医师，硕士生导师，研究方向：临床感染性疾病实验室诊断与应用研究，E-mail:cj1171967@163.com。
更新日期/Last Update: 1900-01-01